Section Review—Cardiovascular & Renal: Recent Developments in Antithrombotic Agents

References

• FAREED J: Antithrombotic drugs in vascular disorders: newer developments and future perspectives. Minerva Angiol. (1992) 17(2):41–47.
   Google Scholar
• FAREED J, WALENGA JM, PIFARRE R: Newer approaches to the pharmacologic management of acute myocardial Infarction. Cardiac Surgery: State of the Art Reviews (1992) 6(1):101–111.
   Google Scholar
• FAREED J, WALENGA JM, PIFARRE R, HOPPENSTEAT D, KOZA M: Some objective considerations for the neutrali-zation of the anticoagulant actions of recombinant hirudin. Haemostasis (1991) 21(1):64–72.
   PubMedGoogle Scholar
• FAREED J, BACHER P, MESSMORE HL, WALENGA JM, HOPPENSTEADT DA, STRANO A, PIFARRE R: Pharma-cological modulation of fibrinolysis by antithrombotic and cardiovascular drugs. Prog. Cardiovasc. Dis. (1992) 6:379–398.
   Google Scholar
• FAREED J, WALENGA JM, HOPPENSTEADT D, RACANELLIA, COYNE E: Chemical and biochemical heterogeneity In low molecular weight heparins: Implications for clinicaluse and standardization. Semin. Thromb. Hemost. (1989) 15:440–463.
   PubMed Web of Science ®Google Scholar
• FAREED J, WALENGA JM, RACANELLI A, HOPPENSTEADT D, HUAN X, MESSMORE HL: Validity of the newly estab-lished low molecular weight heparin standard in cross-referencing low molecular weight heparins. Haemostasis (1988) 18:33–47.
   PubMedGoogle Scholar
• FAREED J, WALENGA JM, HOPPENSTEADT D, HUAN X, RACANELLI A: Study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemostasis (1988) 18:3–15.
   PubMedGoogle Scholar
• FAREED J, WALENGA JM, LASSEN M, BORRIS L, HOPPEN- STEADT D, MURPHY R, AHSAN A, WEBER 5, JORGENSEN LN, HAUCH 0, WILLIE-JORGENSEN P, PIFARRE R: Pharma-cologic profile of a low molecular weight heparin (Enoxaparin): Experimental and clinical validation of the prophylactic antithrombotic effects. Acta Chirur. Scand (1990) 556(Suppl.):75–90.
   Google Scholar
• HULL R, RASKOB G, PINE° G: Subcutaneous low molecu-lar weight heparin compared with continuous intrave-nous heparin in the treatment of proximal vein thrombosis. New Engl J. Med. (1992) 326(15):975–982.
   PubMed Web of Science ®Google Scholar
• MESSMORE HL: Clinical efficacy of heparin fractions: Issues and answers. CRC Clin. Rev. Clin. Lab. Sci. (1986) 23:77–94.
   Web of Science ®Google Scholar
• PRANDONI P, LENSING A, BULLER H, CARTA M, COGO A, VIGO M, CASARA D, RUOL A, TEN GATE JW: Comparison of subcutaneous standard low-molecular weight hepa-rin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet (1992) 339:441–445.
   PubMed Web of Science ®Google Scholar
• HIRSH J, LEVINE M: The development of low molecular weight heparins for clinical use. In: Thrombosis and haemostasis. Verstraete M, et al. (Eds.). Leuven University Press, Leuven (1987):425–448.
   Google Scholar
• HULL R, DELMORE T, CARTER C, HIRSH J, GENTON E,GENT M, TURPIE G, MCLAUGHLIN D: Adjusted subcuta-neous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. New Engl. J. Med. (1983) 306:954–958.
   Google Scholar
• NTEUWENHUIS HK, ALBADA J, BANGA JD, SDCMA JJ: Iden-tification of risk factor for bleeding during treatment of acute venous thrombolysis with heparin or low molecular weight heparin. Blood (1991) 78(9):2337–2343.
   PubMed Web of Science ®Google Scholar
• KELTON JG: Heparin induced thrombocytopenia. Haemostasis (1986) 16:173–186.
   PubMedGoogle Scholar
• SEINER D, KAPSCH D, TOSI E: Heparin induced throm-bocytopenia, thrombosis and haemorrhage. Ann. Surg. (1983) 198:301–305.
   PubMed Web of Science ®Google Scholar
• GRIFFITH GC, NICHOLS G, Jr., ASHER JD, FLANAGAN B:Heparin osteoporosis. J. Am. Med. Assoc. (1965) 193:85–88.
   Web of Science ®Google Scholar
• BARA L, BILLAUD E, GRAMOND G, KHER A, SAMAMA M:Comparative pharmacokinetics of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous dministration. Thromb. Res. (1985) 39:631–636.
   PubMed Web of Science ®Google Scholar
• CHOAY J, PETITOU M, LORN1EAU JC, S1NAY P, CASU B, GATTU G: Structure activity relationship in heparin A synthetic pentasaccharide with high affinity for an-tithrombin III and eliciting high anti-Xa activity. Bio-chem. Biophys. Res. Comm. (1983) 116:491–499.
   Google Scholar
• CHOAY J, LORMEAU jC, PETITOU M, SINAY P, CASU B, ORESTE P, TORRI G, GATTI G: Anti-Xa active heparin oligosaccharides. Thromb. Res. (1980) 18:573–578.
   PubMed Web of Science ®Google Scholar
• ATHA DH, STEPHENS AW, RIMON A, ROSENBERG RD: Sequence variation in heparin octasaccharides with high affinity for antithrombin 111. Biochemistry (1984) 23:5801–5812.
   PubMed Web of Science ®Google Scholar
• BIANCHINI P, OSIMA B, PARMA B, NADER HB, DIETRICHCP: Pharmacological activities of heparins obtained from different tissues. Enrichment of heparin fractions with high lipoprotein lipase, anti-hemolytic and anti-coagulant activities by molecular sieving and an- tithrombin III affinity chromatography. J. Pharrnacol. Exp. Ther. (1982) 220:406–410.
   Google Scholar
• FUSSI F, FEDERLI G: Oligoheteropolysaccharides with heparin-like effects. Ger. Offen. (1977) 2:833–898.
   Google Scholar
• HOOK M, BJORK I, HOP WOOD J, LINDAHL U: Anticoagu-lant activity of heparin. Separation of high activity and low activity heparin species by affinity chromatogra-phy on immobilized antithrombin. FESS Letters (1976) 66:90–93.
   Google Scholar
• HURST RE, POON M, GRIFFITH MJ: Structure-activityrelationships of heparin. J. Clin. Invest. (1983) 72:1042–1045.
   PubMedGoogle Scholar
• BERGQVIST D, MATZSCH T, BURMARK US, FRISELL J, GUILBAUD 0, HALLB00K J, HORN A, LINDHAGEN A, LJUNGER H, LJUNGSTROM KG, ONARHEIM H, R1SBERG B, ToRNGREN S, ORTENWALL P: Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br. J. Surg. (1988) 75(9):888–891.
   PubMed Web of Science ®Google Scholar
• BORRIS LC, HAUCH 0, JORGENSEN LN, LASSEN MR: Enoxaparin versus dextran 70 in the prevention of post-operative deep vein thrombosis after total hip replacement A Danish multicenter study. Proceeding of the Danish Enoxaparin Symposium (Feb 3, 1990).
   Google Scholar
• EUROPEAN FRAXIPARIN STUDY GROUP: Comparison of low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis is patients undergoing abdominal surgery. Br. J. Surg. (1988) 75:1058–1063.
   PubMed Web of Science ®Google Scholar
• HAAS S, STEMBERGER A, FRITSCHE HM, WELZEL D, WOLFH, LECHNER F, BLUMEL G: Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine. Arzneimittel-Forscbung (1987) 37(7):839–843.
   PubMed Web of Science ®Google Scholar
• BAUMGARTNER A, JACOT N, MOSER G, KRAHENBUHL B: Prevention of postoperative deep vein thrombosis by one daily injection of low molecular weight heparin and dihydroergotamine. Vasa (1989) 18(2):152–156.
   PubMedGoogle Scholar
• CAEN JP: A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial. 7bromb. Haemost. (1988) 59(2):216–220.
   Google Scholar
• HARTL P, BRUCKE P, DIENSTL E, VINAZZER H: Prophy-laxis of thromboembolism in general surgery. Com-parison between standard heparin and Fragmin. 7bromb. Res. (1990) 57(4):577–584.
   Google Scholar
• KAKKAR W, STRINGER MD, HEDGES AR, PARKER CJ, WELZEL D, WARD VP, SANDERSON RM, COOPER D, KAK-KAR S: FLxed combinations of low molecular weight or unfractionated heparin plus dihydroergotamine in the prevention of postoperative deep vein thrombosis. Amer. J. Surg. (1989) 157(4):413–418.
   PubMed Web of Science ®Google Scholar
• SAMAMA M, COMBE-TAMAZALI S: Prevention of throm-boembolic disease in general surgery with Enoxaparin. Br. J. Gun. Pract. (1989) 65:9–15.
   Google Scholar
• PLANES A, VOCHELLE N, MAZAS F, MANSAT C, ZUCMAN J, LANDAIS A, POSCARIELLO JC, WEILL D, BUTEL J: Pre-vention of postoperative venous thrombosis. A ran-domized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement Thromb Haemost. (1988) 60(3):407–410.
   Google Scholar
• VERARDI S, CASCIANI CU, NICORA E, FORZANO F, ORIGONE A, VALLE I, CATANIA G, SALANITRI G, SALCUNI P, AZZARONE M: A muhicentre study on LMW-heparin effectiveness in preventing postsurgical thrombosis. Internat. Angiol. (1988) 7(3):19–24.
   PubMed Web of Science ®Google Scholar
• ERIKSSON BI, ZACHRISSON BE, TEGER-NILSSON AC, RISHERG B: Thrombosis prophylaxis with low molecu-lar weight heparin in total hip replacement Br.J. Surg. (1988) 75(11):1053–1057.
   Google Scholar
• LEYVRAZ PF, RICHARD J, BACHMANN F, VAN MELLE G,TREYVAUD JM, LIVIO JJ, CANDARDJIS G: Adjusted versus fixed subcutaneous heparin in the prevention of deep vein thrombosis after total hip replacement New Engl. J Med. (1983) 309:954–958.
   Google Scholar
• MATZSCH T, BERGQVIST D, FREDIN H, HEDNER U: Safetyand efficacy of a low molecular weight heparin (Logi-parin)versus dextran as prophylaxis against thrombo-sis after total hip replacement. Acta Chirur. Scand. (1988) 543:80–84.
   Google Scholar
• MATZSCH T, BERGQVIST D, FREDIN H, HEDNER U: Lowmolecular weight heparin compared with dextran as prophylaxis against thrombosis after total hip replace-ment Acta Cbirur. Scand. (1990) 156(6-7):445–450.
   Google Scholar
• MONREAL M, LAFOZ E, NAVARRO A, GRANERO X, CAJA V,CACERES E, SALVADOR R, RUIZ J: A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and ve-nous thrombosis in patients with hip fracture. J. Trauma (1989) 29(0:873–875.
   PubMedGoogle Scholar
• LINDBLAD B: Prophylaxis of postoperative thromboem-holism with low dose heparin alone or in combination with dyhydroergotamine - A review. Acta Cbirur. Scand. (1988) 154(543):31–42.
   PubMedGoogle Scholar
• VERSTRAETE M: Pharmacotherapeutic aspects of unfrac-tionated and low molecular weight heparins. Drugs (1990) 40(0498–530.
   PubMed Web of Science ®Google Scholar
• HOLMER E, MATTSON C, NILSSON S: Anticoagulant andantithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Tbromb. Res. (1982) 23:475–485.
   Google Scholar
• OCKELFORD PA, CARTER CJ, MITCHELL L, HIRSH J: Dis-cordance between the anti-Xa activity and antithrom-botic activities of an ultra-low molecular weight heparin fraction. Tbromb. Res. (1982) 28:401–409.
   PubMed Web of Science ®Google Scholar
• THOMAS DP, MERTON RE, GRAY E, BARROWCLIFFE TW:The relative antithrombotic effectiveness of heparin, in a low molecular weight heparin and a pentasaccharide fragment in an animal model. Tbromb. Haemost. (1989) 61(2):204–207.
   PubMed Web of Science ®Google Scholar
• WALENGA JM, PETTTOU M, LORMEAU JC: Antithromboticactivity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different throm-bogenic challenges. Thromb. Res. (1987) 46:187–198.
   PubMed Web of Science ®Google Scholar
• KAKKAR VV, MURRAY WJG: Efficacy and safety of lowmolecular weight heparin (CY 216) in preventing post-operative venous thrombo-embolism. A cooperative study. Br. J. Surg. (1985) 72:786–791.
   PubMed Web of Science ®Google Scholar
• LEVINE MN, HIRSH J: An overview of clinical trials with low molecular weight heparin fractions. Acta Chirur. Scand. (1988) 154(543):73–39.
   Google Scholar
• KOPPENHAGEN K, ADOLF J, MA1THES M, TROSTER E, RODER JD, HAAS S, FRITSCHE HM, WOLF H: Low molecu-lar weight heparin and prevention of postoperative thrombosis in abdominal surgery. Thromb. Haemost. (1992) 67(6):627–630.
   PubMed Web of Science ®Google Scholar
• HOPPENSTEADT D, RACANELLI A, WALENGA JM, FAREEDJ: Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin. Semin. Thromb. Hemost. (1989) 15:378–385.
   PubMed Web of Science ®Google Scholar
• BACHER P, WELZEL D, IQBAL 0, HOPPENSTEADT D, CALLAS D, WALENGA JM, FAREED J: The thrombotic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis modeL Thromb. Res. (1992) 66:151–158.
   Google Scholar
• HANKE H, OBERHOFF M, HANKE S, HASSENSTEIN S, KAMENZ J, SCHMID KM, BETZ E, KARSCH KR: Inhibition of cellular proliferation after experimental balloon angioplasty by low molecular weight heparin. Circula-tion (1992) 85:1548–1556.
   PubMed Web of Science ®Google Scholar
• BIANCHINI P: Therapeutic potential of non-heparin glycosaminoglycans of natural origin. Semin. Thromb. Hemost. (1989) 15:365–369.
   PubMed Web of Science ®Google Scholar
• MARCUM JA, ROSENBERG RD: Role of endothelial cellsurface heparin-like polysaccharides. Im Heparin and related polysaccharides. Structure and activities. Ofosu FA, Danishefslcy I, Hirsh J (Eds.). The New York Academy of Sciences, NY (1989):81–94.
   Google Scholar
• SIRTORI CR: Pharmacology of sulfomucopolysaccha-rides in atherosclerosis prevention and treatment In: Selectivity and Risk-Benefit Assessment of Hyperhpidemia Drugs. Ricci G, et al. (Eds.). Raven Press, New York (1982):189–194.
   Google Scholar
• FAREED J, HOPPENSTEADT D, JESKE W, WALENGA JM: An overview of non-heparin glycosaminoglycans as an-tithrombotic agents. In: Blood Coagulation. Potter L (Ed.). Churchill Livingstone, New York (1993).
   Google Scholar
• AGRATI AM, DEBARTOLO G, PALMIERI G: Heparan sulfate Efficacy and safety in patients with chronic venous Insufficiency. Minerva Cardioangiologica (1 99 1) 39(10):395–400.
   Google Scholar
• CARAMELLI L, MIRCHIONI R, CARINI: Effectiveness ofshort-term sulodexide treatment on peripheral vascu-lar disease clinical manifestations. Rivista Europea per le Scienze Mediche e Farmacologiche (1988) 10(1):55–58.
   PubMedGoogle Scholar
• SECCIA M, BELLOMINI MG, GOLETTI 0, TORTORA A, BUCCIANTI P, CHIARUGI M, BERTOLUCCI A, MARTINO MC, MACALUSO C, CAVINA E: The prevention of postop-erative deep venous thrombosis with heparan sulfate per os. A controlled clinical study vs. heparin calcium. Minerva Chirur. (1992) 47(1-2):45–48.
   Google Scholar
• ROMEO S, GRASSO A, COSTANZO C: A controlled clinicalexperiment 'within subjects' with heparan sulfate in Intermittent claudication. Minerva Cardioangiol. (1991) 39(9):345–352.
   Google Scholar
• COFRANCESCO E, BOSCHETFI C, LEONARDI P, CORTEL-LARO M: Dermatan sulphate in acute leukaemia. Lancet (1992) 339(8802):1177–1178.
   PubMedGoogle Scholar
• LANE DA, RYAN K, IRELAND H, CURTIS JR, NURMOHAMEDMT, ICREDIET RT, ROGGEKAMP MC. STEVENS P, TEN CATE
   Google Scholar
• JW: Dermatan sulphate in haemodialysis. Lancet (1992) 339(8789):334–335.
   PubMedGoogle Scholar
• ROWLINGS PA, MANSBERG R, ROZENBERG MC, EVANS S,MURRAY B: The use of a low molecular weight hepari-noid (Org 10172) for extracorporeal procedures in patients with heparin dependent thrombocytopenia and thrombosis. Australian & New Zealand J. Med. (1991) 21(1):52–54.
   PubMedGoogle Scholar
• BERGQVIST D, ICETTUNEN K, FREDIN H, FAUNO P, SUOMALAINEN 0, SOIMAAKALLIO S, KARJALAINEN P, CEDERHOLM C, JENSEN LJ, JUSTESEN T, STIEICEMA JCJ: Thromboprophylaxis in patients with hip fractures. A prospective, randomized, comparative study between Org 10172 and dextran 70. Surgery (1991) 109(5):617–622.
   Google Scholar
• FAREED J, WALENGA JM, IYER L, HOPPENSTEADT D, PIFARRE R: An objective perspective on recombinant hirudin. A new anticoagulant and antithrombotic agent. Blood Coag. Fibrino. (1991) 2:135–147.
   Google Scholar
• HIJIKATA-OKUNOMIYA A, OKAMOTO S: A strategy for arational approach to designing synthetic selective in-hibitors. Sem. Thromb. Hemost. (1992) 18(1):135–149.
   PubMed Web of Science ®Google Scholar
• TAMAO Y, YAMAMOTO T, KIMUMOTO R, ITOH J, HIRATAT, MINE° K, OKAMOTO S: Effect of a selective thrombin-inhibitor MCI-9038 on fibrinolysis in vitro and in vivo. Thromb. Haemost. (1986) 562:28–34.
   Google Scholar
• TAMAO Y, YAMAMOTO T, HIRATA T, KINUGASA M, KIMU-MOTO M: Effect of argipicline (MD-805) on blood coagu-lation. Jpn. Pharmacol. They. (1986) 14:869–874.
   Google Scholar
• MARUYAMA I: Synthetic anticoagulants. Jpn. J. Clin. He-matol. (1990) 31:776–781.
   PubMedGoogle Scholar
• YONEKAWA Y, HANDA H, OKAMOTO S, KAMIJO Y, ODA Y, ISHIKAWA J, TSUDA H, SHIMIZU Y, SATOH M, YAMA-GUCHI T, YANO I, HORIKAWA Y, TSUDA E: Treatment of cerebral infarction in the acute stage with synthetic antithrombin MD80 - clinical study among multiple Institutions. Arch Jpn. Chir. (1986) 55:711–726.
   PubMedGoogle Scholar
• KUMON K, TANAKA K, NAKAJIMA N, NAITO Y, HJUTA T: Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of dis-seminated intravascular coagulation. Crit. Care Med. (1984) 12:1039–1043.
   PubMed Web of Science ®Google Scholar
• OSHIRO T, KANBAYASHI J, KOSAK1 G: Antithrombotictherapy of patient with peripheral arterial reconstruc-tion - clinical study on MD805. Blood & Vessel (1983) 14:216–218.
   Google Scholar
• MATSUO T, KARIO K, KODAMA K, OKAMOTO S: Clinicalapplications of the synthetic thrombin inhibitor, Arga-troban (MD-805). Semin. Thromb. Hemost. (1992) 18(2):155–160.
   PubMed Web of Science ®Google Scholar
• TEGER-NILSSON A, ERIICSSON U, GUSTAFSSON D, BY-LUND R, FAGER G, HELD P: Phase I studies on Inogatran, anew selective thrombin inhibitor. J. Am. Coll. Cardiol. (1995) 117A–118A.
   Google Scholar
• BAJUSZ S, BARABAS E, SZELL E, BAGDY D: Peptide alde-hyde inhibitors of the fibrinogen-thrombin reaction. In: Peptides - Chemistry, Structure and Biology. Meienhofer J (Ed.). Ann Arbor Sci. Publ. 1nc.m Ann Arbor, MI (1975):603–608.
   Google Scholar
• BAJUSZ S, BARABÁS E, TOLNAY P, SZELL E, BAGDY D:Inhibition of thrombin and trypsin by tripeptide alde-hydes. Int. J. Peptide Protein Res. (1978) 12:217–21.
   PubMedGoogle Scholar
• BAJUSZ S, SZELL E, BAGDY D, BARABAS E, DIOSZEGI M, FITTLER Z, JOSZA F, HORVATH G, TOMORI E: US4703036 (1987).
   Google Scholar
• BAJLISZ S, SZELL E, BAGDY D, BARABAS E, HORVATH E, DIOSZEGI M, FITTLER Z, SZABO G, JUHASZ A, TOMORI E, SZILAGYI G: Highly active and selective anticoagulants D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl de-rivative, D-MePhe-Pro-Arg-H. J. Med. Chem. (1990) 33:1729–35.
   PubMed Web of Science ®Google Scholar
• BAGDY D, BARABAS E, BAJUSZ S, SZELL E: In vitro Inhibition of blood coagulation by tripeptide aldehydes - a retrospective screening study focused on the stable D-MePhe-Pro-Arg-HII2SO4. Tbromb. Hemost. (19 9 2) 67(3):325–330.
   Google Scholar
• MARKWARDT F, FINK G, KAISER B, KLOCKING HP, NOWAK G, RICHTER M, STURZEBECHER J: Pharmacologi-cal survey of recombinant hirudin. Pbarmazie (1988) 43:202–207.
   PubMed Web of Science ®Google Scholar
• MARAGANORE JM, BOURDON P, JABLONSKI J, RAMACHANDRAN KL, FENTON JW, 2nd: Design and char-acterization of hirulogs. A novel class of bivalent pep-tide inhibitors of thrombin. Biochemistry (1 99 0) 29:7095-7101.
   Google Scholar
• TOPOL EJ, BONAN R, JEWITT D, SIG WART U, KAKKAR VV, ROTHMAN M, DE BONO D, FERGUSON J, WILLERSON JT, STRONY J, GANZ P, COHEN MD, RAYMOND R, FOX I, MARAGANORE J, ADELMAN B: Use of a direct antithrom-bin, hirulog, in place of heparin during coronary angioplasty. Circulation (1993) 87:1622–1629.
   PubMed Web of Science ®Google Scholar
• PINT M, TAGLIAFERRI A, MANOTTI C, LASAGNI F, RINALDI E, DETTORI AG: Low molecular weight heparin (Alfa LMWH) compared with unfractionated heparin in pre-vention of deep-vein thrombosis after hip fractures. Intl. Angiol. (1989) 8(3):134–139.
   PubMed Web of Science ®Google Scholar
• SORENSEN JV, LASSEN MR, BORRIS LC, RAHR HB, JENSEN HP, HOPPENSTEADT D, WALENGA JM, FAREED J: Reduc-tion of plasma levels of prothrombin fragments 1 and 2 during thrombophylaxis with a low-molecular-weight heparin. Blood Coagulation and Fibrinolysis (1992) 3(1):55–59.
   PubMedGoogle Scholar
• TURPIE AGG, LEVINE MN, HIRSH J, CARTER CJ, JAY RM,POWERS PJ, ANDREW M, HULL RD, GENT M: A random-ized controlled trial of low molecular weight heparin (Enoxaparin) to prevent deep vein thrombosis in pa-tients undergoing elective hip surgery. New Engl. J. Med. (1987) 315:925–929.
   Web of Science ®Google Scholar
• LEFKOVITS J, TOPOL EJ: Direct thrombin inhibitors incardiovascular medicine. Circulation (1994) 90(3):1522–1536.
   PubMed Web of Science ®Google Scholar
• THEROUX P, LIDON R: Anticoagulants and their use inacute ischemic syndromes. In: Textbook of Inteiventional Cardiology. Topol EJ (Ed.). WB Saunders Co., Philadelphia, PA (1994).
   Google Scholar
• SALTIEL E, WARD A: Ticlopidine; a review of its pbarma-codynamic and pharmacoldnetic properties and thera-peutic efficacy in platelet-dependent disease states. Drugs (1987) 34:222–262.
   PubMed Web of Science ®Google Scholar
• WALENGA JM, PIFARRE R, FAREED J: Recombinant hirudin as an antithrombotic agent. Drugs Future (1990) 15:267–270.
   Google Scholar
• PYTELE R, PIERSCHBACHER MS, GINSBERG MU, PLOW EF, RUOSLATHI E: Platelet membrane glycoprotein 11b/111a - member of a family of RGD specific adhesion recep-tors. Science (1986) 231:1559–1562.
   PubMed Web of Science ®Google Scholar
• PHILIPS DR, CHARO IF, SCARBOROUGH RM: GPIIb-Ma - the responsive integrin. Cell (1991) 65:359–362.
   PubMed Web of Science ®Google Scholar
• RUGGERI ZM, HOUGHTON RA, RUSSEL SR, ZIMMERMAN TS: Inhibition of platelet function with synthetic pep-tide designed to be high affinity antagonist of fibrino-gen binding to platelets. Proc. Natl. Acad. Sci. USA (1986) 83:5708–5712.
   PubMed Web of Science ®Google Scholar
• MICKELSON JK, SIMPSON PJ, CRONIN M, HOMEISTER JW, LAYWELL E, KITZEN J, LUCCHESI BR: Antiplatelet anti-body [7E3 f(ablz) prevents rethrombosis after recom-binant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine modleL Circu-lation (1990) 81:617–627.
   Google Scholar
• BOCK LC, GRIFFIN LC, LATHAM JA, VERMAAS EH, TOOLE JJ: Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature (1992) 355(6360):564–6.
   PubMed Web of Science ®Google Scholar
• MACAYA RF, SCHULTZE P, SMITH FW, ROE JA, FEIGON J: Thrombin-binding DNA aptamer forms a uninaolecular quadruplex structure in solution.. Proc. Natl. Acad. Sci. USA (1993) 90:3745–3749.
   PubMed Web of Science ®Google Scholar
• PABORSKY LR, MCCURDY SN, GRIFFIN LC, TOOLE IL LEUNG LLK: The single-stranded DNA aptamer binding-site of human thrombin. J. Biol. Chem. (1993) 268:20808.
   PubMed Web of Science ®Google Scholar
• LI WX, KAPLAN AV, GRANT GW, TOOLE JJ, LEUNG LLK: A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation. Blood (1994) 83(3):677–682.
   PubMed Web of Science ®Google Scholar
• LATHAM JA, JOHNSON R, TOOLED: The application of a modified nucleotide in aptamer selection - novel throm-bin aptamers containing 5-(1-pentyny1)-2'-deoxyurid-ine. Nucleic Acids Research (1994) 22(14):2817–2822.
   PubMed Web of Science ®Google Scholar
• KUBIK MF, STEPHENS AW, SCHNEIDER D, MARLAR R, TASSET D: High-affinity RNA ligands to human a-throm-bin. Nucleic Acids Research (1994) 22(13):2619–2626.
   PubMed Web of Science ®Google Scholar
• COCCHERI S, BIAGI G: Defibrotide. Cardiovasc. Drug Reviews (1991) 9(2):172–196.
   Google Scholar
• FAREED J, WALENGA JM, HOPPENSTEADT DA, KUMAR A, ULUTIN 0, CORNELLI U: Pharrnacologic profiling of dellbrotide in experimental models. Semin. Thromb. Hemost. (1988) 14:27–37.
   PubMed Web of Science ®Google Scholar
• BRACHT F, SCHROR K: Isolation and identification of aptamers from defibrotide that act as thrombin antago-nists in vitro. Biochem. Biophys. Res. Com . (1994) 200(2):933–937. Jawed Fareed, Demetra D Callas, Debra Hoppensteadt, Walter Jeske, Jeanine M Walenga, Departments of Pathology and Pharmacology, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA.
   Google Scholar